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Abstract
Treatment of hypertension improves cardiovascular, renal, and cerebrovascular outcomes. However, the benefit of
treatment may be different according to the patients’ characteristics. Additionally, the target blood pressure or
initial drug choice should be customized according to the special conditions of the hypertensive patients. In this
part III, we reviewed previous data and presented recommendations for some special populations such as diabetes
mellitus, chronic kidney disease, elderly people, and cardio-cerebrovascular disease.
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Hypertension in special situations
White coat hypertension and masked hypertension
Recommendations Class Level References
It is reasonable to exclude the presence of
white coat hypertension (HTN) by using either
ambulatory blood pressure monitoring
(ABPM) or home blood pressure monitoring
(HBPM) before initiation of antihypertensive
medication.
I C [1]
It is reasonable to check ABPM or HBPM
before change of antihypertensive drug
treatment intensification.
IIa C [2]
It is reasonable to check ABPM or HBPM for
the adults with prehypertension or suspected
of masked HTN
IIa B [3]
For the patients with masked HTN, lifestyle
modifications and antihypertensive drug
therapy may be reasonable.
IIa C [4]
It is important to detect white coat HTN [high office
blood pressure (BP) but normal out-of-office BP] and
masked HTN (normal office BP but high out-of-office BP)
using out-of-office BP measurement. White coat effect is
more frequently observed in women and older adults. If
the diagnosis is not made correctly, it may result in side
effects associated with unnecessary medication. Therefore,
it is recommended to exclude white coat HTN as much as
possible before initiating antihypertensive medication. In
patients who are already on medication, it is important to
check the effectiveness before adding medication for more
aggressive treatment.
For the patients with white coat HTN, lifestyle
modifications and regular BP monitoring are recommended.
Although there is little evidence, pharmacological treatment
as well as lifestyle modifications could be considered when
metabolic disturbances and/or subclinical organ damage
occurs with white coat HTN [5]. Pharmacological treatment
for masked HTN may be beneficial because it has shown a
similar cardiovascular (CV) risk profile as sustained HTN [4,
6, 7]. Masked HTN has a higher risk of cardiovascular
disease (CVD), thus thorough treatment is considered.
There are no clear criteria for the diagnosis of masked HTN
and the threshold or reproducibility [8, 9]. However, masked
HTN is more common in smokers or in patients with work-
related stress and it is observed in about 30% among patients
with prehypertension. Special attention should be paid to the
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patients with metabolic syndrome with high cardiovascular
risk, target organ damage, diabetes mellitus (DM), chronic
kidney disease (CKD), smokers, heavy drinking, exercise in-
duced hypertension, and occupational stress for the diagnosis
and treatment of masked HTN.
Metabolic syndrome
Recommendations Class Level References
Lifestyle modifications such as diet, weight
reduction, and exercise are recommended for
the hypertensive patients with metabolic
syndrome.
I B [10, 11]
Angiotensin converting enzyme (ACE)
inhibitors/angiotensin II receptor blockers
(ARBs) or calcium channel blockers can be
considered as the antihypertensive agents for
patients with metabolic syndrome.
IIa C
Antihypertensive medication is not
recommended for prehypertensive patients
with metabolic syndrome.
III A [12–14]
Many hypertensive patients have obesity and
metabolic abnormalities with alterations of lipid and
glucose metabolism. Furthermore, subclinical organ
damage is common in these patients. Metabolic
syndrome consists of abdominal obesity, dyslipidemia,
dysglycemia, and raised BP. The criteria for clinical
diagnosis of metabolic syndrome are: 1) abdominal
obesity; 2) fasting glucose ≥100 mg/dL (diabetes
included); 3) triglycerides ≥150 mg/dL; 4) high-density
lipoprotein (HDL)-cholesterol < 40mg/dL in men and <
50mg/dL in women; and 5) BP ≥130/85mmHg [15].
Presence of three or more of these criteria confirms the
diagnosis of metabolic syndrome. Abdominal obesity is
usually estimated by the measurement of waist circum-
ference. However, cut-off points of waist circumference
for abdominal obesity in Korean adults are not estab-
lished. Cut-off points of waist circumference, which are
commonly used, are 1) ≥90 cm in men; ≥80 cm in
women (International Obesity Task Force criteria for
Asian-Pacific population); and 2) ≥90 cm in men; ≥85
cm in women (Korean adult specific values) [15, 16].
The prevalence of metabolic syndrome has been
increased over the last 10 years, as reported in the Korean
National Health and Nutritional Survey. The prevalence of
metabolic syndrome in Korean aged over 30 years is 30.5%
[17]. However, the prevalence of metabolic syndrome is
twice as high among the hypertensive patients [18].
In Western countries, people with metabolic syndrome
have at 1.5–2-fold higher risk of CV events and death
than those without metabolic syndrome and incident
diabetes is 5-fold higher in people with metabolic
syndrome [19, 20].
In Asian countries, metabolic syndrome had a relative
risk of incident diabetes of 3–4, which is a little lower
compared to that in Western countries [21, 22]. The most
powerful predictor of incident diabetes is hyperglycemia
in people with metabolic syndrome. However, metabolic
syndrome, even without hyperglycemia, was associated
with an increased risk of incident diabetes; the relative
risk is 2.4 in Japanese population [22]. In addition to
metabolic syndrome, HTN is associated with twice higher
risk of incident diabetes [23, 24].
In hypertensive patients with metabolic syndrome,
antihypertensive treatment is used to prevent CV
morbidity and mortality, while lowering or preventing
incident diabetes. Antihypertensive treatment in non-
diabetic patients with metabolic syndrome is discussed
below, while that treatment for diabetic/CVD patients
with metabolic syndrome is discussed in other respective
sections of the special situations chapter. Lifestyle modifi-
cations, especially weight reduction and regular exercise,
are strongly recommended in all hypertensive patients, as
they decrease BP, improve metabolic abnormalities, and
delay incident diabetes [10, 11].
Hypertensive patients should be treated with
antihypertensive medication as well as lifestyle
modification, but there is no evidence available for the
drug treatment in prehypertensive patients [12–14].
Antihypertensive drugs should lower BP effectively as well
as have favorable or neutral effects on insulin sensitivity and
metabolic abnormalities. Thus, ACE inhibitors, ARBs, and
calcium channel blockers are preferred. Among beta-
blockers, vasodilating beta-blockers such as carvedilol and
nebivolol can be used as combination therapy with ACE in-
hibitors/ARBs.
Thiazides and thiazide-like diuretics are avoided as
monotherapy or at high doses, but are used as combin-
ation therapy or at low doses. High dose diuretics can
induce hypokalemia and new onset diabetes, and have
unfavorable effects on lipid metabolism. The preferred
approach is combination of ACE inhibitors/ARBs with
diuretics to minimize their unfavorable effects on
glucose and lipid metabolism.
Diabetes mellitus
Recommendations Class Level References
In patients with DM and HTN, systolic BP
should be less than 140mmHg.
I A [25–29]
In patients with DM and HTN, diastolic BP
should be less than 85mmHg.
I B [30–32]
In patients with DM and CVD, BP should be
less than 130/80mmHg.
IIa C [33]
In hypertensive patients with DM, all
hypertensive drugs are recommended as first-
line antihypertensive agents.
I A [27, 32]
ACE inhibitors or ARBs are recommended for
patients with microalbuminuria or proteinuria.
I B [34–36]
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The prevalence of HTN is two-fold in diabetic patients
compared to that in the general population, and the occur-
rence of diabetes is 2.5-fold higher in hypertensive patients
[37, 38]. The coexistence of HTN and diabetes causes the
progression of CVD, stroke, and renal disease. The high
risk of HTN in diabetic patients is related with weight
gain, hyperinsulinemia, sympathetic hyperactivity, and salt
retention. Additionally, hyperglycemia itself can further in-
crease the risk of HTN by increasing arterial stiffness and
progressing atherosclerosis. The nocturnal dipping disap-
pears in diabetic patients, and it is associated with subclin-
ical organ damage such as left ventricular hypertrophy
(LVH) and microalbuminuria. In the UK Prospective
Diabetes Study (UKPDS)-36, each 10mmHg decrease in
mean systolic blood pressure (SBP) was associated with
risk reductions of 12% for any complication related to
diabetes, 15% for deaths related to diabetes, 11% for myo-
cardial infarction, and 13% for microvascular complica-
tions [39]. Previous studies have shown that appropriate
BP control can reduce the incidence of CVD [34, 40–43].
The recommended target for BP in diabetic patients is
< 140/85mmHg. In previous guidelines, the recommended BP
was < 130/80mmHg or< 140/80mmHg in diabetic patients
[34, 40–43]. However, recent studies have failed to show any
beneficial effect on CV outcome with strict BP control [28,
44]. Due to the beneficial effect of strict BP control in
Systolic Blood Pressure Interventional Trial (SPRINT)-
eligible patients among Action to Control Cardiovascular
Risk in Diabetes (ACCORD) study, BP should be lowered less
than 130/80mmHg in patients with diabetes and CVD [33].
According to a recent meta-analysis, all classes of antihy-
pertensive agents, such as ACE inhibitors, ARBs, calcium
channel blockers, beta-blockers and diuretics can be used
in diabetic patients [31]. However, ACE inhibitors/ARBs
are recommended as first-line antihypertensive therapy in
patients with microalbuminuria or proteinuria [32, 34–36].
The superiority of one antihypertensive class over others is
controversial. The choice of a particular class is less signifi-
cant in practice because two or more antihypertensives
should be combined in order to obtain sufficient decrease
in BP in most diabetic patients. However, the combination
of beta-blockers and thiazide diuretics is not recommended
as it could worsen glucose control by increasing insulin re-
sistance. Sodium-glucose co-transporter-2 (SGLT-2) inhibi-
tor can decreased BP, thus it should be used cautiously
with antihypertensive medication [45–47].
Hypertension in older adults
Recommendations Class Level References
SBP goal of less than 140 mmHg is
recommended for noninstitutionalized,
ambulatory community-dwelling adults
(≥65 years of age).
IIa B [48, 49]
The treatment of HTN in older adults reduces the risk
of CVD and mortality. The benefit of treatment is also
observed with regard to isolated systolic HTN.
Accordingly, HTN needs to be actively diagnosed and
treated in older adults.
However, the benefit of pharmacological treatment for
grade I hypertensive patients older than 80 years remains
controversial. Thus, the characteristics of the patient
should be considered. The characteristic findings of elderly
hypertensive patients are increased SBP and widened pulse
pressure due to increased central arterial stiffness.
Moreover, atherosclerotic renovascular HTN is commonly
observed. Non-dipper, increased daytime BP variability, and
orthostatic or postprandial hypotension are also charac-
teristic findings in elderly patients with HTN.
The non-pharmacological treatment in elderly HTN pa-
tients is effective; however, the impact on the patient’s qual-
ity of life should be considered [50]. Target SBP for older
patients is < 140mmHg, but orthostatic hypotension
should be avoided [51]. Additional studies are required to
confirm the target SBP among the frail older patients. The
initial dose of the pharmacological treatment is reduced by
half in younger patients, and gradually increased. Elderly
hypertensive patients without co-morbidities should be
treated with ACE inhibitors, ARBs, calcium channel
blockers, and diuretics [52–55]. Beta-blockers do not im-
prove prognosis as much as other drug classes in elderly
hypertensive patients. However, beta-blockers would be ef-
fective in patients with angina, heart failure, or tachycardia.
Combination therapy with two or more drugs should be
considered if the BP is not controlled with monotherapy.
Patients with co-morbidities require special consideration.
It is safe to slowly lower the BP in elderly patients. Compli-
cations caused by medication should be monitored when
increasing the drug dose. Orthostatic hypotension should
be periodically checked by positional BP measurement.
Cardiac diseases
Coronary artery disease
Recommendations Class Level References
In adults with coronary artery disease (CAD)
and HTN, a BP target of 130/80mmHg is
recommended.
IIa B [56–60]
HTN is a major risk factor of CAD and is associated
with the occurrence of myocardial infarction. The incidence
of ischemic heart disease increases when SBP is > 140
mmHg and mortality increases when SBP is > 120 mmHg
[61, 62]. Considering J-curve phenomenon, it is important
not to decrease DBP < 70mmHg, especially in older
patients, multivessel disease without revascularization, and
diabetic patients. The preferred drugs within 1month after
acute myocardial infarction are beta-blockers and ACE
inhibitors [63, 64]. Any first line antihypertensive drugs are
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available in patients with ischemic heart disease, but beta-
blockers and calcium channel blockers are initially consid-
ered for the symptomatic CAD.
Chronic heart failure
Recommendations Class Level References
In adults with HTN and increased risk of heart
failure, a BP target of 130/80mmHg is
recommended.
I B [65]
Adults with heart failure with reduced
ejection fraction (HFrEF) and hypertension
should be prescribed to attain a BP of 130/80
mmHg.
I B [66]
HTN is the most important risk factor in heart failure
[67–69]. Strict BP control in hypertensive patients with
HFrEF is helpful for the prevention of heart failure
aggravation and CV events as well as mortality reduction
[70]. Most BP-lowering drugs such as diuretics, beta-
blockers, ACE inhibitors, and ARBs are effective in the
prevention of heart failure. In decompensated heart failure
patients, a 25% reduction of BP can be achieved with vaso-
dilator and loop diuretics within few hours. For the HFrEF
and hypertensive patients, beta-blockers, ACE inhibitors,
ARBs, and aldosterone antagonists are recommended
considering the beneficial effects on mortality reduction
and re-hospitalization. Thiazides can be used for the
additional BP lowering. A dihydropyridine calcium channel
blocker can be used, but in contrast, a non-dihydropyridine
calcium channel blocker such as verapamil or diltiazem
should not be used because of negative inotropic effects
[71]. HTN is also a risk factor for heart failure with pre-
served ejection fraction (HFpEF) and it is likely that strict
BP control is helpful for the CV events and mortality
reduction in HFpEF patients.
Atrial fibrillation
Hypertension is one of the risk factor for atrial
fibrillation and atrial fibrillation is frequently observed in
hypertensive patients, but it can be prevented with BP
control [72, 73]. Patients with HTN and atrial fibrillation
have a high risk of thromboembolism and need chronic
antithrombotic treatment if no contraindications are
present [74]. Recently, antithrombotics such as direct
thrombin inhibitors (dabigatran) and factor Xa inhibitors
(rivaroxaban, apixaban, edoxaban) have been shown
to be effective and relatively safe compared with the
classic antithrombotic therapy using warfarin [75, 76].
In patients with atrial fibrillation and HTN, lowering
the BP can decrease the incidence of fatal bleeding
during antithrombotic treatment. However, BP should
be maintained above 120/70 mmHg [77, 78].
Vascular diseases
Carotid atherosclerosis
The progression of carotid atherosclerosis can be
prevented by lowering BP. For this purpose, calcium
channel blockers and ACE inhibitors are superior to
beta-blockers and diuretics [79, 80].
Arterial stiffness
Most antihypertensive drugs decrease vascular stiffness
because BP reduction can decrease vascular wall stress
and pulse wave velocity. However, it is not clear whether
there is any difference in the reduction of arterial stiffness
according to drug class [81–83]. Renin-angiotensin-
aldosterone inhibitors can decrease the pulse wave vel-
ocity, independent of BP reduction [84–86]. Vasodilating
beta-blockers are better for central aortic SBP reduction
compared to atenolol. Although an improvement in
vascular stiffness with antihypertensive drugs has been
reported in numerous studies, it is still uncertain whether
the improvement in vascular stiffness is closely related to
the CV benefits, except for CKD patients [87]. Further
studies are needed to determine the relationship between
vascular stiffness and CV outcomes.
Peripheral arterial disease
It is important to control the CVD risk factors because
patients with peripheral arterial disease (PAD) have a
higher risk of CV mortality (10-year mortality of 40%)
[88]. Lowering the SBP decreases the leg amputation
rate and mortality in hypertensive patients with diabetes
and PAD [39]. The target BP is around 130/80 mmHg in
patients with PAD according to a recent meta-analysis
and the SPRINT trial [89–91].
Lifestyle modifications such as salt restriction, weight
control, moderation of alcohol intake, and regular aerobic
exercise are very important. Pharmacological treatment
consists of ACE inhibitors, ARBs, and aspirin [92, 93].
ACE inhibitors decrease long-term CV events from either
BP lowering effects or indirect BP lowering effects [41,
94]. However, other drugs are also effective in the reduction
of CV events associated with BP lowering [90, 94–97].
Furthermore, it is important to evaluate and manage CV
risk factors other than HTN, such as lipid and blood
glucose. The appropriate drugs are determined according
to the presence of heart failure or coronary artery disease.
In general, beta-blockers are relatively contraindicated to
avoid worsening of PAD symptoms. However, some reports
have revealed that beta-blockers do not aggravate the symp-
toms in patients with mild to moderate PAD Therefore,
beta-blockers are effective in PAD patients with co-existing
ischemic heart disease or tachycardia [98, 99]. Renal artery
stenosis is frequently observed in patients with HTN and
PAD. Overall, ongoing evaluation of the disease and
monitoring are needed during HTN treatment [100].
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Aortic disease
In patients with aortic aneurysm, it is strongly recommended
to lower the BP to the lowest levels tolerated by the patient
[101]. Beta-blockers are preferred owing to their ability to re-
duce the maximum ventricular ejection of the left ventricle,
as well as the BP and heart rate. In acute aortic syndrome,
including aortic dissection, the BP and heart rate should be
controlled aggressively with antihypertensive medication
including beta-blockers. BP should be lower less than
140mmHg within 1 h and maintained less than 120
mmHg thereafter. It is recommended to reduce BP around
130/80mmHg in patients with atherosclerosis [60, 91].
Chronic kidney disease
Recommendations Class Level References
In adults with HTN and CKD (with albuminuria
≥30 mg/day, or albumin-to-creatinine ratio≥
30 mg/g), treatment with ACE inhibitor or ARB
may be reasonable.
IIa B [30, 102–
104]
CKD is defined as the presence of kidney injury for >
3 months, with markers of kidney injury being a
decrease in estimated glomerular filtration rate (eGFR)
(< 60mL/min/1.73 m2), urinary abnormalities including
albuminuria (> 30 mg/day or albumin-to-creatinine ra-
tio > 30 mg/g), hematuria and pyuria, electrolyte distur-
bances caused by tubular dysfunction, renal structural
abnormalities detected by imaging or biopsy procedures,
and renal transplants. CKD patients frequently suffer
from HTN; hence, the rate of decline in renal function
and the incidence of CV complications can be reduced
with HTN control [105, 106]. However, we still need to
determine the target BP levels, optimal tools to be used
in HTN control, and the real benefits and risks associ-
ated with treatment [107].
The recent 2017 American College of Cardiology/
American Heart Association/American Society of
Hypertension guideline recommended a BP target of
< 130/80 mmHg in all CKD patients [108]. However,
previous major clinical trials failed to show any beneficial
effect of strict BP control in non-proteinuric CKD
patients. Accordingly, CKD patients without albuminuria
are recommended to maintain BP < 140/90 mmHg
[109–111]. On the other hand, randomized controlled
trials have suggested that a lower target may be bene-
ficial in proteinuric CKD patients. Thus, we re-
commend that CKD patients with albuminuria should be
treated to maintain SBP < 130 mmHg [30, 112–114]. BP
target levels do not depend on the presence of DM.
Lifestyle modifications should be used as a basic tool for
BP control in all hypertensive CKD patients. Although no
large scale randomized controlled trials have reported the
effects of lifestyle modification on clinical outcomes in
CKD patients, the beneficial effects can be inferred from
the results reported in previous studies in general
populations [115–121]. The 2011–2014 Korea National
Health and Nutrition Examination Survey showed that
body mass index (BMI) associated with the risk of CKD
[122]. We recommend achieving or maintaining a healthy
weight (BMI 20 to 25), lowering salt intake to < 90mmol
(< 2 g) per day of sodium unless contraindicated,
undertaking regular exercise compatible with CV health
and tolerance, limiting alcohol intake to < 2 standard drinks
per day for men and < 1 standard drink per day for women.
Pharmacological treatment in CKD patients includes
single or multiple antihypertensive therapies to achieve
the target BP. Although any antihypertensive can be
used in CKD patients, ACE inhibitors or ARBs have
been reported to be renoprotective owing to the
reduction in albuminuria and improvement in the rate
of decline of the glomerular filtration rate [30, 102–104].
Thus, we recommend that ACE inhibitors or ARBs
should be used in CKD patients with albuminuria. ACE
inhibitors or ARBs are preferred in both diabetic and
non-diabetic CKD patients with either microalbuminuria
(30–300 mg/day) or macroalbuminuria (> 300 mg/day).
However, the combination of ACEIs and ARBs in CKD
patients are not recommended.
It should be noted that there are occasions when the
BP target and the preferred agent mentioned above may
be inappropriate. Treatment should be individualized
based on the patient’s age, presence of albuminuria and
comorbidities. Diabetic or elderly patients need to be
questioned about orthostatic dizziness because of the
possibility of postural hypotension [123–125]. ACE
inhibitors and ARBs are contraindicated in bilateral
renal artery stenosis, and should be used with caution in
patients with diffuse atherosclerosis.
Cerebrovascular diseases
The risk of ischemic and hemorrhagic stroke increases
proportionally as the BP increases, with HTN being the
most common modifiable risk factor in stroke prevention
and having the highest attributable risk for stroke in the
population. HTN treatment, particularly SBP control, will
remarkably reduce the incidence of stroke. For the
management of high BP, lifestyle modifications (weight
loss, low-fat diet, reduced salt intake, exercise or physical
activity, moderation of alcohol intake, and smoking cessa-
tion) must routinely precede drug therapy. According to
an epidemiologic study, with each increase of 20/10
mmHg from BP level of 115/75mmHg or higher, deaths
from stroke increased at least two-fold. Conversely, a 10/
5mmHg decrease in BP resulted in a 40% decrease in
deaths from stroke [61]. In addition, a meta-analysis of
clinical studies showed that stroke risk was expected to
decrease by about 30–40% by lowering the BP by 10/5
mmHg with drug therapy, regardless of the past history of
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the patient [63, 126, 127]. For the primary prevention of
stroke, it is recommended to maintain the BP < 140/90
mmHg. Although it remains unknown whether a specific
drug or class is superior to other antihypertensive drugs in
the prevention of stroke, a limited number of reports have
shown that calcium channel blockers, ACE inhibitors, or
ARBs are superior to beta-blockers [128]. However, for
the primary prevention of stroke, it is most important to
lower the BP based on an individualized approach for each
patient rather than the choice of a specific drug or drug
class [129].
Acute ischemic stroke
Recommendations Class Level References
If blood pressure is high in patients with
acute ischemic stroke suitable for intravenous
thrombolytic therapy, we recommend
lowering the BP to less than 185/110mmHg
before initiating intravenous thrombolytic
therapy.
I B [130, 131]
BP in patients with acute ischemic stroke
should be reduced to 185/110 mmHg or
lower before intravenous thrombolytic
therapy and maintained below 180/105
mmHg for 24 h.
I B [132]
Starting or resuming anti-hypertensive medica-
tion during hospitalization in ischemic stroke
patients with BP greater than 140/90mmHg
who are neurologically stable is safe and rea-
sonable to improve long-term BP control, un-
less contraindicated.
IIa B [133, 134]
In patients with BP of 220/120mmHg or
higher who did not receive intravenous
thrombolysis or thrombectomy, and have no
comorbid conditions requiring acute
antihypertensive treatment, the benefit of
initiating or reinitiating treatment of HTN
within the first 48 to 72 h is uncertain. It
might be reasonable to lower BP by 15%
during the first 24 h after onset of stroke
IIb C [135]
In patients with BP less than 220/120mmHg
who did not receive intravenous thrombolysis
or endovascular treatment and do not have a
comorbid condition requiring acute
antihypertensive treatment, treatment of HTN
within the first 48 to 72 h after an acute
ischemic stroke is not effective to prevent
death or dependency.
III A [133, 134,
136]
In general, the BP rises in acute ischemic stroke [137]. It
is assumed that BP increases owing to the acute stress,
previous HTN, and the automatic compensation in an
attempt to maintain perfusion of the brain tissue in the
ischemic state. Thus, continuous BP monitoring is
important, as a sudden drop in BP should be avoided to
maintain the appropriate perfusion to the brain. Although
a previous study has shown that ARB administration for 1
week in stroke patients within a week of the attack
reduced the mortality after a 12-month period, large-scale
studies are needed [41, 138]. Conversely, because active
treatment against rising BP would reduce the perfusion to
the ischemic area and expand the area of the infarction, it
is undesirable to lower the BP actively within the period of
1 week of the acute ischemic stroke [7, 139].
When thrombolytic therapy is used in the hyperacute
period of an ischemic stroke, the incidence of bleeding is
closely related to the BP before and after thrombolysis;
hence, the target BP should be < 185/110mmHg. For
thrombolytic therapy using tissue-plasminogen activator
(t-PA), the drug could only be administered after the BP
was < 185/110mmHg. The antihypertensive regimens
consisting of intravenous drugs such as labetalol, nicar-
dipine, diltiazem, nitroglycerin, and nitroprusside are
recommended [140–143]. In the acute phase of the
ischemic stroke, it is recommended to use antihyperten-
sive drugs only when BP is > 220/120mmHg, to avoid a
decrease in the cerebral perfusion around the infarct
area [144]. Target BP levels should be 85–90% of the
baseline BP. However, in cases of hypertensive encepha-
lopathy, aortic dissection, acute renal failure, acute
pulmonary edema, and acute myocardial infarction, it is
recommended to lower the BP sufficiently in order to
prevent complications associated with the elevated BP
itself [140, 141].
Acute parenchymal hemorrhage
Recommendations Class Level References
If the SBP of a patient with acute
parenchymal hemorrhage within 6 h of the
onset is 150–220mmHg, immediate lowering
of SBP may be considered with a target SBP
above 140mmHg.
IIb A [145, 146]
In adults with intracerebral hemorrhage who
present with SBP greater than 220 mmHg, it is
reasonable to use continuous intravenous
drug infusion and close BP monitoring to
lower SBP.
IIa C [147–149]
From a theoretical viewpoint, the optimal BP treatment
in the acute phase of a parenchymal hemorrhage could
prevent re-bleeding and subsequent expansion of a
hematoma and edema; hence, it is recommended to lower
the BP during the acute phase of the hemorrhage. If the
SBP is ≥200mmHg or if the mean BP is ≥150mmHg, the
BP should be lowered by monitoring BP every 5min. In
patients with increased intracranial pressure, BP should be
lowered by maintaining the cerebral perfusion pressure
between 60 and 80mmHg using an intracranial pressure
monitoring device only when the SBP is > 180mmHg or
the mean BP is > 30mmHg. Because a sudden drop of BP
during the acute phase is associated with higher mortality
rates, it is recommended to maintain a cerebral perfusion
pressure of ≥60mmHg. When the SBP is 180mmHg or the
mean BP is 130mmHg—as long as there is no evidence of
increased intracranial pressure, with the assessment of BP
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every 15min—the BP should be lowered below the level of
80% of baseline BP, < 160/90mmHg, or mean BP < 110
mmHg. Antihypertensive regimens including intravenous
drugs such as labetalol, nicardipine, diltiazem, nitroglycerin,
and nitroprusside are recommended [150]. Despite recent
studies showing benefits associated with lowering BP to less
than 140mmHg during the acute phase, the supportive evi-
dence is insufficient; hence, the BP should not be reduced
to below 140mmHg [145, 146, 151].
Secondary prevention of stroke
Recommendations Class Level References
Patients with previously treated HTN who
experience stroke or transient ischemic attack
should be advised to resume HTN medication
a few days after stroke for the prevention of
recurrent stroke or vascular disease.
I A [76, 152,
153]
We recommend thiazide diuretic, ACE
inhibitor/ARB or combination treatment
consisting of a thiazide diuretic plus ACE
inhibitor/ARB for the treatment of HTN in
stroke or transient ischemic stroke patients.
I A [76, 152,
154]
It is reasonable to consider calcium channel
blockers to control HTN in stroke or transient
ischemic stroke patients.
IIa C [155, 156]
Patients without HTN treatment are advised
to start HTN treatment several days after
stroke or transient ischemic attack to prevent
stroke and vascular disease recurrence if BP is
above 140/90mmHg.
I B [152–154]
The usefulness of antihypertensive treatment
has not been established when blood
pressure is below 140/90mmHg after stroke
or transient ischemic attack.
IIb C [157]
Patients with lacunar infarction, a BP goal of
less than 130/80mmHg may be reasonable.
IIb B [158]
HTN treatment as a measure of secondary prevention
after stroke significantly reduces mortality and the
recurrence of stroke or vascular diseases [126, 154, 159,
160]. Regardless of the history of HTN, treatment of HTN
after stroke significantly reduces the mortality and
complications associated with HTN. Lifestyle modifications
should be maintained in addition to the pharmacological
treatment. For the selection of the optimal antihypertensive
drugs, the individual characteristics of the patient such as
the presence of extracranial cerebrovascular disease, kidney
disease, heart disease, and diabetes should be considered. In
a recent meta-analysis, a combination therapy using ACE
inhibitors and diuretics is preferred [154].
Erectile dysfunction
Erectile dysfunction is considered to be one of the a CV
risk factors associated with poor prognosis [161].
Therefore, risk factors such as DM, dyslipidemia, and
smoking should be controlled aggressively, and lifestyle
modifications should be recommended to the patients
with erectile dysfunction to reduce the CV risk. However,
most cases of the erectile dysfunction are not properly
diagnosed by doctors and only a minority of patients seeks
medical advice. Therefore, more cautious history taking
and comprehensive management are required for the
improvement of CV prognosis among hypertensive
patients with erectile dysfunction [162].
In general, the prevalence of erectile dysfunction
associated with antihypertensive medication is reported to
be 0–25%, but the prevalence may be affected by
underlying conditions such as endothelial dysfunction,
and oxidative stress [163]. Erectile dysfunction related to
antihypertensive medication is usually observed within 4
weeks. Beta-blockers and diuretics are known to cause
erectile dysfunction, and ACE inhibitors and calcium
channel blockers are neutral, whereas ARBs are reported
to be beneficial [164]. A vasodilating beta-blocker such as
carvedilol, nebivolol, and labetalol may be an alternative
for hypertensive patients with erectile dysfunction. A
phosphodiesterase-5 (PDE5) inhibitor is relatively safe and
effective in patients with erectile dysfunction caused by
antihypertensive medications, and the additional BP
lowering effect is negligible. However, the BP after admin-
istration of PDE5 inhibitors should be closely monitored
and PDE5 inhibitors must not be co-administered with
nitrates [165, 166].
Pregnancy
High BP occurring during pregnancy can be divided into
four categories: 1) chronic HTN in pregnancy: existing
HTN or taking antihypertensive medication before the
20th week of pregnancy; 2) gestational HTN: newly
diagnosed HTN after the 20th week of pregnancy in the
absence of proteinuria; 3) pre-eclampsia: HTN diag-
nosed after 20 weeks of pregnancy accompanied by pro-
teinuria (albumin more than 300 mg in 24 h urine or
urine albumin/creatinine ratio of 300 mg/g or greater);
and 4) pre-eclampsia superimposed on chronic HTN:
pre-eclampsia diagnosed in the chronic HTN pregnant
women. Based on the BP level, it is classified as mild:
140–149/90–99mmHg, moderate: 150–159/100–109
mmHg, and severe: 160/110 mmHg or higher.
Generally, there are few controversies regarding
drug treatment for BP of > 160/110 mmHg or higher.
Previous studies have reported that patients with BP
> 150/95 mmHg are more likely to be hospitalized due
to incident stroke during the peripartum period
[167, 168]. In pregnancy, BP should be controlled
below 150/100 mmHg, but it is not recommended to
lower DBP below 80 mmHg [169, 170].
Antihypertensive drugs used during pregnancy are
methyldopa, labetalol, and nifedipine. Specific drugs are
selected in consideration of the drug class previously
used, their side effects, and the risk of teratogenicity.
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Beta-blockers can cause fetal growth retardation, thus
they can be used later in the pregnancy. Diuretics should
be prescribed cautiously because they can induce volume
depletion. ACE inhibitors or ARBs may increase the risk
of congenital malformations in pregnancy, it is recom-
mended to replace these drugs before pregnancy or
when planning a pregnancy. If a pregnancy is detected
during the administration of ACE inhibitors or ARBs,
they should be discontinued and replaced promptly. In
emergency situations, such as pre-eclampsia, intravenous
labetalol is recommended but intravenous nitroprusside
or nitroglycerin could be alternatives. After delivery, BP
should be controlled below 140/90 mmHg.
Gestational HTN and preeclampsia are associated with
an increased risk of developing HTN after delivery and
pre-eclampsia is a risk factor for CVD. Patients with a
history of pre-eclampsia have about a two-fold risk of
ischemic heart disease, stroke, and venous thrombosis
and a four-fold risk of developing sustained HTN. Espe-
cially in cases of preeclampsia within 32 weeks of gesta-
tion, stillbirth, and fetal growth retardation, the risk of
HTN increases much more. Thus, active BP control and
lifestyle modification even after delivery is strongly
recommended for patients with HTN during pregnancy.
Women and hypertension
In younger populations, women have lower prevalence
of HTN than men. But after menopause, the prevalence
of HTN in women increases rapidly as reaches the
prevalence in men in their 60s and prevalence becomes
even higher than that in men in their 70s or 80s. As for
age, the increase in pulse pressure is the same between
men and women, however, the systolic and diastolic BPs
are higher in women after menopause. Care should be
taken in the diagnosis of HTN in menopausal women,
because white coat HTN occurs more frequently in
these women.
After menopause, weight gain, hormonal changes, and
psychological changes occur [171]. In particular, the
deficiency of estrogen induces menopausal symptoms and
CV events [172]. In the past, hormone replacement therapy
(HRT) was widely recommended after menopause, but
clinical studies found no beneficial effects for CVD or it
sometimes worsened, and therefore, HRT is no longer
recommended. Because HRT can increase BP, women who
have a greater chance of developing HTN need to be
carefully observed for a few months [173].
There is no difference in HTN treatment between
women and men. Additionally, there is no difference in
BP reduction and drug effects between women and men
[174]. Oral contraceptives can increase BP in some
subjects, and the occurrence of accelerated or malignant
HTN is rare. Family history of HTN, past history of
HTN during pregnancy, kidney disease, obesity, or oral
contraceptive use can increase the risk of BP increase.
Therefore, in the early period of oral contraceptive use,
BP needs to be carefully monitored, while periodic
measurements are recommended thereafter.
Sleep apnea
Recommendations Class Level References
Consider continuous positive pressure
ventilation for patients with sleep apnea with
HTN.
IIb B [175–178]
Continuous positive airway pressure (CPAP) therapy is
effective in improving sleep apnea. However, in studies
concerning sleep apnea, CPAP was reported cause a 2–3
mmHg decrease of BP, and the effects differed according
to adherence, disease severity, and daytime sleepiness
[175–177, 179].
Cognitive impairment
Recommendations Class Level References
Consider HTN treatment to prevent cognitive
dysfunction and dementia in adult
hypertensive patients.
IIa B [55, 180–
184]
Vascular disease and its related factors are the major risk
factors of dementia, including Alzheimer’s disease [185,
186]. HTN is a major risk factor for ischemic microvascular
disease and cerebral white matter disease, which can lead
to cognitive dysfunction by damaging the cerebral nerve
circuit [187–189]. It has been reported that Alzheimer’s
dementia and other dementia were less likely to develop
when systolic BP was well controlled. Furthermore, it was
more effective in preventing dementia when treatment was
started individuals in their 50s rather than in those treated
in their 60s [185, 190]. In most randomized clinical trials,
HTN treatment did not have a negative impact on
cognitive dysfunction and dementia. However, results from
studies have been inconsistent due to lack of study power,
insufficient follow-up duration, and inadequate tools for
cognitive evaluation [55, 180–184].
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